Clinical Trial Update: Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating disitamab vedotin with toripalimab for hormone receptor-positive, HER2-low breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• Toripalimab (Toripalimab)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Breast Neoplasms | Phase 2 | Status: WITHDRAWN